PDF《北斗嘉药业股份有限公司》

2 Chairman'

s Statement

3 Report of the Directors

7 Management Discussion and Analysis

17 Profile of Directors, Supervisors and Senior Management

19 Report of the Supervisory Committee

22 Corporate Governance Report

23 Independent Auditor'

s Report

30 Consolidated Statement of Profit or Loss and Other Comprehensive Income

34 Consolidated Statement of Financial Position

35 Consolidated Statement of Changes in Equity

36 Consolidated Statement of Cash Flows

37 Notes to the Consolidated Financial Statements

38 Financial Summary

100 2 EXECUTIVE DIRECTORS Cui Bingyan Fang Yao (Appointed on

15 June 2018) Guo Aiqun (Appointed on

15 June 2018) Wang Shaoyan (Ceased on

15 June 2018) Jiang Xiaobin (Ceased on

15 June 2018) NON-EXECUTIVE DIRECTORS Shi Peng Cao Yang INDEPENDENT NON-EXECUTIVE ?DIRECTORS Gao Zhikai (Resigned on

12 April 2019) Hui Lai Yam (Resigned on

15 April 2019) Chen Youfang (Appointed on

15 June 2018) Yang Yulin (Resigned on

1 April 2018) Zhu Tianxiang (Appointed on

24 April 2019) SUPERVISORS Lin Xiarong Li Li (Appointed on

15 June 2018) Zhao Haitao (Appointed on

15 June 2018) Yang Lixue (Ceased on

15 June 2018) Han Xue (Ceased on

15 June 2018) COMPANY SECRETARY Ng Chenhuei AUDIT COMMITTEE Gao ZhiKai (Resigned on

12 April 2019) Hui Lai Yam (Resigned on

15 April 2019) Chen Youfang (Appointed on

15 June 2018) Yang Yulin (Resigned on

1 April 2018) Zhu Tianxiang (Appointed on

24 April 2019) COMPLIANCE OFFICER Cui Bingyan AUTHORIZED REPRESENTATIVES Cui Bingyan Fang Yao GEM STOCK CODE

8197 AUTHORIZED PERSON TO ACCEPT ? SERVICE OF PROCESS AND NOTICE Cui Bingyan AUDITORS PAN-CHINA (H.K.) CPA LIMITED LEGAL ADVISORS AS TO ? HONG KONG LAWS Li &

Partners PRINCIPAL BANKER China Construction Bank Jilin Railway Branch Bank of China (Hong Kong) HONG KONG BRANCH SHARE ? REGISTRATION AND TRANSFER OFFICE Computershare Hong Kong Investor Services Limited 17M Floor Hopewell Centre

183 Queen'

s Road East Hong Kong REGISTERED OFFICE No.3, No.

2 Road Jilin Hi-Tech Development Zone Jilin City Jilin Province PRC PRINCIPAL PLACE OF BUSINESS ? IN HONG KONG 12/F, Kam Sang Building 255C257 Des Voeux Road Central, Hong Kong

3 BUSINESS REVIEW AND PROSPECTS On behalf of Board of Directors (the Board ) of Baytacare Pharmaceutical Co., Ltd. (the Company ), I hereby present to our shareholders the annual report of the Company and its subsidiaries (collectively referred to as Group ) for the year ended

31 December 2018. Business Review During the period under review, the lack of momentum in global economic growth continued. the Chinese economy growth will be stable but may change. The Chinese government has continued to promote supply- side reforms, including the introduction of a series of steady growth measures, which have gradually increased the positive factors in the economic structure. The Group'

s business is classified into four main segments: A. Chinese Herbs Business;

B. Medicines Business;

C. Medicines Sourcing/Trading Business;

and D. Big Data Business. A. Chinese Herbs Business After thorough study and consideration of the Feasibility Study Report and the potential markets and costs of different Chinese herbs, the Company considered that in addition to ginseng, the plantation and harvesting of Sehisandra (五味子) would also be one of the key products of the Company under this segment. Sehisandrais a precious Chinese herb and considered as one of the

50 fundamental herbs which have multi-functions and wide application for health-related issue. Sehisandra can harvest and ready for sales one year after the plantation and can harvest over a period of